1. Home
  2. SOUNW vs ERNAW Comparison

SOUNW vs ERNAW Comparison

Compare SOUNW & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SoundHound AI Inc. Warrant

SOUNW

SoundHound AI Inc. Warrant

HOLD

Current Price

$0.47

Market Cap

0.0

Sector

Technology

ML Signal

HOLD

Logo Ernexa Therapeutics Inc. Warrants

ERNAW

Ernexa Therapeutics Inc. Warrants

HOLD

Current Price

$0.02

Market Cap

0.0

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOUNW
ERNAW
Founded
2005
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
SOUNW
ERNAW
Price
$0.47
$0.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 35.8K
30.4K
Earning Date
02-27-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 73.08
31.29
EPS
★ N/A
N/A
Revenue
N/A
★ $582,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.02
52 Week High
$8.98
$0.23

Technical Indicators

Market Signals
Indicator
SOUNW
ERNAW
Relative Strength Index (RSI) 32.89 45.61
Support Level $0.30 $0.02
Resistance Level $3.51 $0.08
Average True Range (ATR) 0.07 0.01
MACD 0.02 0.00
Stochastic Oscillator 44.36 14.12

Price Performance

Historical Comparison
SOUNW
ERNAW

About SOUNW SoundHound AI Inc. Warrant

SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.

About ERNAW Ernexa Therapeutics Inc. Warrants

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: